Development of novel vaccine vectors: Chimpanzee adenoviral vectors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of novel vaccine vectors: Chimpanzee adenoviral vectors
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 14, Issue 7, Pages 1679-1685
Publisher
Informa UK Limited
Online
2018-01-05
DOI
10.1080/21645515.2017.1419108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimpanzee Adenovirus Vector Ebola Vaccine
- (2017) Julie E. Ledgerwood et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia
- (2017) Stephen B. Kennedy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
- (2016) Tommy Rampling et al. JOURNAL OF INFECTIOUS DISEASES
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
- (2016) Milagritos D Tapia et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
- (2016) Olga De Santis et al. LANCET INFECTIOUS DISEASES
- Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs
- (2016) Julio Alonso-Padilla et al. MOLECULAR THERAPY
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
- (2016) Katie Ewer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via “Antigen Capsid-Incorporation” strategy
- (2016) Linlin Gu et al. VIROLOGY
- Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab
- (2016) Man Xing et al. Oncotarget
- Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development
- (2015) Cheng Cheng et al. VACCINE
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
- (2014) Daphne A Stanley et al. NATURE MEDICINE
- Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds
- (2014) Michael Behr et al. PLoS One
- Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
- (2014) Emma-Jo Hayton et al. PLoS One
- Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection
- (2014) Anitra L. Farrow et al. PLoS Neglected Tropical Diseases
- Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China
- (2014) Xiang Wang et al. Emerging Microbes & Infections
- Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
- (2013) Stefania Capone et al. Expert Review of Vaccines
- Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy
- (2013) Chuan Jin et al. HUMAN GENE THERAPY
- Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization
- (2013) K. M. Quinn et al. JOURNAL OF IMMUNOLOGY
- Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
- (2012) Susanne H. Sheehy et al. PLoS One
- Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon
- (2012) Xingui Tian et al. PLoS One
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
- (2012) S. Colloca et al. Science Translational Medicine
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
- (2012) E. Barnes et al. Science Translational Medicine
- Cross-Species Transmission of a Novel Adenovirus Associated with a Fulminant Pneumonia Outbreak in a New World Monkey Colony
- (2011) Eunice C. Chen et al. PLoS Pathogens
- Development of a Targeted Gene Vector Platform Based on Simian Adenovirus Serotype 24
- (2010) N. Belousova et al. JOURNAL OF VIROLOGY
- An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector
- (2010) Dongming Zhou et al. Nature Protocols
- Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome
- (2010) D. G. Gibson et al. SCIENCE
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
- (2010) J.E. Ledgerwood et al. VACCINE
- A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines
- (2009) Daniela Peruzzi et al. VACCINE
- International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
- (2009) T. Christopher Mast et al. VACCINE
- Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates
- (2009) Soumitra Roy et al. PLoS Pathogens
- Complete Chemical Synthesis, Assembly, and Cloning of a Mycoplasma genitalium Genome
- (2008) D. G. Gibson et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started